The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression
Types of Chemotherapy Regimens | Download Table
Cureus | Fibroadenoma Arising in Axillary Ectopic Breast Tissue. A Diagnostic Challenge | Authors
George DEDOUSSIS | Professor of cellular and molecular biology | PhD | Harokopio University, Kallithéa | HUA | Department of Nutrition and Dietetics | Research profile - Page 5
Michael ALEXIS | University Cesar Vallejo, Lima | UCV | Lima | Research profile
Immunohistochemical findings for matrix proteins. (a) Strong and... | Download Scientific Diagram
Dionysios DIMAS | Research profile
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer
Schematic drawing illustrating the relationship between main members of... | Download Scientific Diagram
Eftychia Lekka - Senior Investigator, Drug Discovery - Biovista | LinkedIn
George DEDOUSSIS | Professor of cellular and molecular biology | PhD | Harokopio University, Kallithéa | HUA | Department of Nutrition and Dietetics | Research profile - Page 5
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression
Diagnostics | Free Full-Text | Metaplastic Matrix-Producing Carcinoma and Apocrine Lobular Carcinoma In Situ Associated with Microglandular Adenosis: A Unique Case Report
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression
Psychosocial Adjustment to Illness Scale: Factor structure, reliability, and validity assessment in a sample of Greek breast can
PDF) Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity | Ioannis Charalampopoulos - Academia.edu
Marinos Tsiatas MD, PhD, BSc(Biol) - Director, Medical Oncology Department and Clinical Trials Unit - Athens Medical Grοup | LinkedIn
Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast cancer - Baxevanis - 1993 - Cancer - Wiley Online Library
![Patients with pathological response have longer TTR [48 months (17–84)]... | Download Scientific Diagram](https://www.researchgate.net/publication/43132163/figure/fig2/AS:330189788729344@1455734788034/Patients-with-pathological-response-have-longer-TTR-48-months-17-84-than-patients.png "Patients with pathological response have longer TTR [48 months (17–84)]... | Download Scientific Diagram")
Patients with pathological response have longer TTR [48 months (17–84)]... | Download Scientific Diagram
Panteleimon KOUNTOURAKIS | Medical Doctor | MD PhD | Medical Oncology | Research profile
Ioannis BOUTAS | Medical Doctor | Doctor of Medicine | National and Kapodistrian University of Athens, Athens | uoa | Division of Obstetrics - Gynecology III | Research profile
Efrosini KATSANOU | Researcher C' | PhD in Molecular Endocrinology/Pharmacology | Benaki Phytopathological Institute, Athens | Department of Pesticides Control and Phytopharmacy | Research profile
Eftychia Lekka - Senior Investigator, Drug Discovery - Biovista | LinkedIn
Andreas SCORILAS | National and Kapodistrian University of Athens, Athens | uoa | Department of Biochemistry and Molecular Biology | Research profile - Page 3
Psychosocial Adjustment to Illness Scale: Factor structure, reliability, and validity assessment in a sample of Greek breast cancer patients: Women & Health: Vol 57, No 6
